- Open-label Phase III study comparing atezolizumab + chemotherapy + bevacizumab (ABCP group) versus chemotherapy + bevacizumab (BCP group) in metastatic and chemotherapy-naïve NSCLC patients- ABCP group achieved significantly longer PFS (8.3 versus 6.8 months) and OS (19.2 versus 14.7 months) than BCP group, regardless of PD-L1 expression and EGFR/ALK genetic alteration status. The gene discussed is ALK; the disease is non-small cell lung carcinoma.